FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.986,40 +211,02 (+0,56%) Nasdaq
15.282,01 -319,49 (-2,05%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,31 +0,58 (+0,70%) Bitcoin EUR
60.134,08 +493,08 (+0,83%)
Sirona Biochem Corp. (SBM.V)
| Chiusura precedente | 0,0650 |
| Aperto | 0,0600 |
| Denaro | 0,0550 x 0 |
| Lettera | 0,0650 x 0 |
| Min-Max giorno | 0,0600 - 0,0600 |
| Intervallo di 52 settimane | 0,0550 - 0,2150 |
| Volume | |
| Media Volume | 50.938 |
| Capitalizzazione | 15,308M |
| Beta (5 anni mensile) | -0,44 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0000 |
| Prossima data utili | 27 giu 2024 - 01 lug 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 27 dic 2006 |
| Stima target 1A | N/D |
GlobeNewswireSirona Biochem Corporate Update
VANCOUVER, British Columbia, July 13, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update: Dear shareholders, We are pleased to provide an update on the progress we have made over the last months: Corporate Strategic Planning One of our communicated objectives in 2022 and the first half of 2023 was to conduct a thorough strategic review of the company. We are pleased to announce that this goal has been accomplished. We have
- GlobeNewswire
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- June 28, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is excited to announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology (ICGEB). The compounds, generated by Sirona's subsidiary TFChem, are aimed at expanding Sirona's existing library of antiviral drug candidates. The ICG
- GlobeNewswire
Sirona Biochem Engages Atheln Inc. to Strengthen Business Development Initiatives
VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to announce it has contracted Atheln Inc. ("Atheln"), a leading US consulting firm, to bolster and facilitate Sirona's business activities. This strategic initiative comes at an opportune time, as Sirona prepares for the highly anticipated BIO International 2023 conference in Boston, where it will showcase its groundbreaking anti-aging compound, TFC-1326.
